Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Inclusion Criteria: * Signed informed consent * Unresectable or metastatic pancreatic cancer * Persistent cancer after at least one prior standard of care chemotherapy for advanced stage disease * 18 - 70 years of age * ECOG performance status of 0 or 1 * Life expectancy greater than 3 months * Satisfactory organ and bone marrow function * Meets blood coagulation parameters * Male and Female subjects of reproductive potential agree to use approved contraceptive methods Exclusion Criteria: * Participation in a therapeutic investigational study within 4 weeks prior to the screening visit * Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion * Active invasive cancer other than pancreatic cancer * HIV, HCV, or HBV infections * Active autoimmune disease requiring immunosuppressive therapy within 4 weeks prior to screening visit, with exception of thyroid replacement * Ongoing or active infection * Planned concurrent treatment with systemic high dose corticosteroids * Patients requiring supplemental oxygen therapy * Prior therapy with gene modified cells * Previous experimental therapy with SS1 moiety, murine or chimeric antibodies * History of allergy to murine proteins * History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) * Clinically significant pericardial effusion, CHF, or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study * Pregnant or breastfeeding women